People who are uninsured or part of a minority racial or ethnic group are underscreened for cervical cancer. Mailing them a self-sample kit may help.

The U.S. Food and Drug Administration OK'd an at-home test last month, and it is expected to hit the market within a few months WEDNESDAY, June 11, 2025 (HealthDay News) — Women will flock to an ...

As part of the 10 Year Health Plan, the UK Government has announced it will offer home-testing kits for cervical cancer ...

A blood test based on whole-genome sequencing achieved 99% sensitivity and specificity for detecting HPV-positive head and neck cancer. Early postoperative detection of circulating tumor DNA ...

Starting from when someone reaches the age of 30, Medicare Part B and Medicare Advantage plans will cover HPV testing along with a Pap test once every 5 years. This lasts until a person is over ...

A new tampon that tests for HPV and STIs could transform women’s health. Valentina Milanova believes products like the diagnostic tampon could help eradicate cervical cancer for good ...

Women who have rarely or who have never attended a cervical screening appointment will now be offered the opportunity to use an at-home HPV testing kit.

"If it wasn't for that, I wouldn't be here to tell my story." Toni Smith from Eastwood, in Nottinghamshire, went for a routine smear test when she was 28-years-old and believes doing so saved her life ...

After becoming popular in the wake of the Me Too movement, at-home sexual assault kits are still facing legal battles. Things could get more complicated after an FDA move.

Ovulation test kits are more accurate when you have a regular cycle because it’s easier to predict the midway point of your cycle. But don’t worry — ovulation testing can still work if you ...

Genital warts are caused by the human papillomavirus, a common sexually transmitted infection, yet many people know little about them. It’s worth knowing that the HPV vaccine protects against ...

A University of Chicago spinout has raised $4 million in seed funding to develop a unique, saliva-based test for oral cancers. OrisDX's funding was led by Revere Partners and strategic investment ...